血脂平胶囊对高血脂模型金黄地鼠血脂水平的影响及机制研究  

Study on the Effect and Mechanism of Xuezhiping Capsule on Blood Lipid Levels of High Blood Lipid Model Golden Hamsters

作　　者：申强[1] 张海晶[2] 杨明华[1] 孙晓波[2] 孙桂波[2] 

机构地区：[1]哈尔滨商业大学生命科学与环境科学研究中心,哈尔滨150076 [2]中国医学科学院北京协和医学院药用植物研究所,北京100193

出　　处：《中国药房》2017年第16期2212-2215,共4页China Pharmacy

摘　　要：目的:研究血脂平胶囊对高血脂模型金黄地鼠血脂水平的影响及其可能机制。方法:将金黄地鼠随机分为正常对照组、模型组、阿托伐他汀组(3 mg/kg)、联用组(血脂平胶囊1.3 g/kg+阿托伐他汀1.5 mg/kg)和血脂平胶囊低、中、高剂量组(血脂平胶囊1.3、2.6、5.2 g/kg),每组10只。正常对照组地鼠给予普通饲料,其他组地鼠给予高脂饲料建立高血脂模型,2周后同时ig给予相应药物,正常对照组和模型组地鼠ig等体积的蒸馏水,每日1次,连续给药4周。末次给药后,检测各组地鼠血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、游离脂肪酸(FFA)],肝组织中脂质代谢相关基因(PPAR-α、CYP7A1、ACOX、SREBP-1c、ACC1)m RNA及蛋白表达。结果:与正常对照组比较,模型组地鼠血清TC、TG、LDL-C、FFA含量增加,HDL-C含量降低,PPAR-α、CYP7A1、ACOX m RNA及蛋白表达减弱,SREBP-1c、ACC1 m RNA及蛋白表达增强(P<0.05)。与模型组比较,血脂平胶囊高剂量组、阿托伐他汀组和联用组地鼠上述指标均明显改善(血脂平高剂量组HDL-C除外)(P<0.05);血脂平胶囊中剂量组地鼠TC、TG、FFA含量和PPAR-α、CYP7A1、ACOX、ACC1 m RNA及CYP7A1、SREBP-1c、ACC1蛋白表达均明显改善(P<0.05);血脂平胶囊低剂量组地鼠TC、TG含量和PPAR-αm RNA及CYP7A1、SREBP-1c蛋白表达均明显改善(P<0.05)。结论:血脂平胶囊具有降血脂作用,其机制可能与激活PPAR-α和抑制SREBP-1c信号通路有关。OBJECTIVE： To study the effect and its possible mechanism of Xuezhiping capsule on blood lipid levels of high blood lipid model golden hamsters. METHODS： Golden hamsters were randomly divided into normal control group, model group, atorvastatin group （3 mg/kg） , combination group （Xuezhiping capsule 1.3 g/kg＋atorvastatin 1.5 mg/kg） , Xuezhiping capsule low-dose, medium-dose, high-dose groups （Xuezhiping capsule 1.3, 2.6, 5.2 g/kg）, 10 in each group. Hamsters in normal control group received normal diet, the other groups were given high-fat diet to establish high blood lipid model. Then relevant drugs were intragastrieally given 2 weeks later. Normal control group and model group were intragastrically given equal volume of distilled wa- ter, once a day, for 4 weeks. After last administration, blood lipid indexes （TG, TC, HDL-C, LDL-C, FFA）, mRNA and protein expressions of lipid metabolism related genes （PPAR-α, CYP7A1, ACOX, SREBP-1c, ACC1） were detected. RESULTS： Com- pared with normal control group, serum contents of TC, TG, LDL-C, FFA in model group increased, HDL-C content decreased; PPAR-α, CYPTA1, ACOX mRNA and protein expressions were weakened, SREBP-1c, ACC1 mRNA and protein expressions were enhanced （P〈0.05）. Compared with model group, above-mentioned indexes were obviously improved in Xuezhiping capsule high-dose group, atorvastatin group and combination group （except for HDL-C in Xuezhiping capsule high-dose group） （P〈 0.05） ; TC, TG, FFA contents, and PPAR-α, CYP7A1, ACOX, ACC1 mRNA, and CYPTA1, SREBP-1c, ACC1 protein were obviously improved in Xuezhiping capsule medium-dose group （P〈0.05） ; TC, TG contents, and PPAR-α mRNA, and CYPTA1, SREBP-1c protein were obviously improved in Xuezhiping capsule low-dose group （P〈0.05）. CONCLUSIONS： Xuezhiping capsule has a promising effect of lowering blood lipid, the mechanism may be related to activating PPAR-α and inhibiting SREBP-1c signaling pathway.

关 键 词：血脂平胶囊 高血脂 降血脂 作用机制 金黄地鼠 

分 类 号：R965[医药卫生—药理学]